Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines

Lu, Lantian; Duong, Viet Tram; Shalash, Ahmed O.; Skwarczynski, Mariusz; Tóth, István

doi:10.3390/vaccines9060563

Cited by 56 publications

(44 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The shape plays a role in the particle circulation time, biodistribution, and immune targeting ( Thorp et al, 2020 ). The surface charge influences solubility, uptake by APCs, and DC maturation ( Jazayeri et al, 2021 ; Lu et al, 2021 ).…”

Section: Optimizing Nanoparticle’s Propertiesmentioning

confidence: 99%

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Yang

Sun

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Autoimmune disease is a chronic inflammatory disease caused by disorders of immune regulation. Antigen-specific immunotherapy has the potential to inhibit the autoreactivity of inflammatory T cells and induce antigen-specific immune suppression without impairing normal immune function, offering an ideal strategy for autoimmune disease treatment. Tolerogenic dendritic cells (Tol DCs) with immunoregulatory functions play important roles in inducing immune tolerance. However, the effective generation of tolerogenic DCs in vivo remains a great challenge. The application of nanoparticle-based drug delivery systems in autoimmune disease treatment can increase the efficiency of inducing antigen-specific tolerance in vivo. In this review, we discuss multiple nanoparticles, with a focus on their potential in treatment of autoimmune diseases. We also discuss how the physical properties of nanoparticles influence their therapeutic efficacy.

show abstract

Section: Optimizing Nanoparticle’s Propertiesmentioning

confidence: 99%

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Yang

Sun

2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…HSA attachment onto PLGA and CSPLGA particles was carried out using carbodiimide chemistry to obtain HSA-PLGA and HSA-CSPLGA, respectively. Briefly, HSA was reacted to the carboxylic acids on PLGA or amines on CSPLGA in one reaction step, enabled by the fact that proteins have an abundance of both amine and carboxylic acid groups at the C-terminus, N-terminus, and amino acid side chains [ 31 ]. Dried particles were resuspended in deionized water and sonicated at 20% amplitude to disperse, and concentration was obtained using a hemocytometer.…”

Section: Methodsmentioning

confidence: 99%

Dual Coating of Chitosan and Albumin Negates the Protein Corona-Induced Reduced Vascular Adhesion of Targeted PLGA Microparticles in Human Blood

Lopez-Cazares

Eniola‐Adefeso

2022

Pharmaceutics

View full text Add to dashboard Cite

Vascular-targeted carriers (VTCs) have the potential to localize therapeutics and imaging agents to inflamed, diseased sites. Poly (lactic-co-glycolic acid) (PLGA) is a negatively charged copolymer commonly used to construct VTCs due to its biodegradability and FDA approval. Unfortunately, PLGA VTCs experienced reduced adhesion to inflamed endothelium in the presence of human plasma proteins. In this study, PLGA microparticles were coated with chitosan (CS), human serum albumin (HSA), or both (HSA-CS) to improve adhesion. The binding of sialyl Lewis A (a ligand for E-selectin)-targeted PLGA, HSA-PLGA, CSPLGA, and HSA-CSPLGA to activated endothelial cells was evaluated in red blood cells in buffer or plasma flow conditions. PLGA VTCs with HSA-only coating showed improvement and experienced 35–52% adhesion in plasma compared to plasma-free buffer conditions across all shear rates. PLGA VTCs with dual coating—CS and HSA—maintained 80% of their adhesion after exposure to plasma at low and intermediate shears and ≈50% at high shear. Notably, the protein corona characterization showed increases at the 75 and 150 kDa band intensities for HSA-PLGA and HSA-CSPLGA, which could correlate to histidine-rich glycoprotein and immunoglobulin G. The changes in protein corona on HSA-coated particles seem to positively influence particle binding, emphasizing the importance of understanding plasma protein–particle interactions.

show abstract

“…Protein-based VLPs act as natural NPs that can be extensively used in vaccine development due to ease in design, self-assembly, and high stability ( Nguyen and Tolia, 2021 ). Three different methods are used to attach antigens for presentation on NPs, (1) tag coupling ( van Oosten et al, 2021 ), (2) chemical conjugation ( Lu et al, 2021 ), and (3) genetic fusion ( Antanasijevic et al, 2020 ). These techniques enable the platform to be decorated with a variety of antigens, leading to increased size and presentation ( Nguyen and Tolia, 2021 ).…”

Section: Protein Nanoparticles For Vaccine Developmentmentioning

confidence: 99%

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.

show abstract

Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines

Cited by 56 publications

References 169 publications

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases

Dual Coating of Chitosan and Albumin Negates the Protein Corona-Induced Reduced Vascular Adhesion of Targeted PLGA Microparticles in Human Blood

Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases

Contact Info

Product

Resources

About